CSCIED

期刊目次

加入编委

期刊订阅

添加您的邮件地址以接收即将发行期刊数据:

Open Access Article

International Journal of Clinical Research. 2023; 7: (4) ; 87-89 ; DOI: 10.12208/j.ijcr.20230173.

Effect of rilalutide combined with metformin in the treatment of diabetes
利拉鲁肽联合二甲双胍治疗糖尿病的效果

作者: 代文娟 *

河北中石油中心医院 河北廊坊

*通讯作者: 代文娟,单位:河北中石油中心医院 河北廊坊;

发布时间: 2023-04-13 总浏览量: 364

摘要

目的 研究利拉鲁肽联合二甲双胍对于治疗糖尿病的效果。方法 选取我院80例糖尿病患者作为本次研究对象,按计算机表法将其分为2组(对照组、实验组)。对照组患者服用二甲双胍治疗,实验组患者在对照组基础上联合利拉鲁肽治疗,将两组临床治疗效果、不良反应发生情况、相关血糖指标水平以及脂肪因子水平进行比较。结果 实验组临床治疗总有效率高于对照组,不良反应发生率低于对照组,实验组患者相关血糖指标水平以及脂肪因子水平优于对照组,组间有差异,P<0.05。结论 对于糖尿病患者而言,利拉鲁肽联合二甲双胍效果显著,减少不良反应发生,用药安全性较高,改善相关指标,具有推广价值。

关键词: 利拉鲁肽;二甲双胍;糖尿病;治疗效果

Abstract

Objective: To study the effect of rilalutide combined with metformin in the treatment of diabetes.
Methods: 80 patients with diabetes in our hospital were selected as the subjects of this study and divided into two groups (control group and experimental group) according to the computer table method. The patients in the control group were treated with metformin, while the patients in the experimental group were treated with liraglutide on the basis of the control group. The clinical treatment effect, adverse reactions, related blood glucose index levels, and adipose factor levels of the two groups were compared.
Results: The total effective rate of clinical treatment in the experimental group was higher than that in the control group, and the incidence of adverse reactions was lower than that in the control group. The levels of related blood glucose indicators and adipose factors in the experimental group were better than those in the control group, with differences between the groups (P<0.05).
Conclusion  : For patients with diabetes, the combination of rilalutide and metformin has a significant effect, reduces the occurrence of adverse reactions, has high drug safety, improves relevant indicators, and is worth popularizing.

Key words: Lilalutide; Metformin; Diabetes; treatment effect

参考文献 References

[1] 杨威.对体质量超标2型糖尿病患者采取利拉鲁肽联合二甲双胍治疗的临床分析[J].中国医药指南,2022, 20(36):62-65.

[2] 徐爽,童慧昕,梁琳琅,孔媛.二甲双胍、达格列净、利拉鲁肽联合治疗新诊断超重或肥胖2型糖尿病患者临床疗效及安全性[J].临床军医杂志,2022, 50(12): 1252-1254+1257.

[3] 梁桂敏,苏冬雪,邵宁,陈萍,王莹,马晶.利拉鲁肽治疗初诊肥胖2型糖尿病患者的效果[J].中国当代医药,2022, 29(32):68-71.

[4] 陈晓丹,黄敏,甘丽萍.利拉鲁肽联合二甲双胍治疗2型糖尿病疗效探讨[J].糖尿病新世界,2022,25(21):107-110.

[5] 刘佩旺,廖远志,丘毅铭.利拉鲁肽联合二甲双胍对糖尿病治疗的效果分析[J].糖尿病新世界,2022,25(19): 118-121.

[6] 常丽君.利拉鲁肽注射液联合二甲双胍缓释片治疗肥胖2型糖尿病的效果分析[J].基层医学论坛,2022,26(25): 18-20.

[7] 郭智慧,李会,董钊,金思彤,周艳茹,杨春伟,王彩宁.二甲双胍联合利拉鲁肽干预糖尿病前期的中期效果观察[J].中国医院用药评价与分析,2022,22(07):839-841+846.

[8] 陈荣.利拉鲁肽联合二甲双胍治疗2型糖尿病肥胖患者的效果观察[J].中国现代药物应用,2022,16(12):31-34.

引用本文

代文娟, 利拉鲁肽联合二甲双胍治疗糖尿病的效果[J]. 国际临床研究杂志, 2023; 7: (4) : 87-89.